Delayed short-course treatment with teriparatide (PTH(1-34)) improves femoral allograft healing by enhancing intramembranous bone formation at the graft-host junction.

Takahata M, Schwarz EM, Chen T, O'Keefe RJ, Awad HA

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jan 2012Cited by 28 (Europe PMC)

PMID21956542PMCIDPMC3253332DOI10.1002/jbmr.518PepBankPUB-21956542

Source link PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, only high-dose daily teriparatide produced significant healing effects among the tested doses.
In plain wordsIn mice, only the highest daily teriparatide dose produced significant effects on allograft healing.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedDose-dependent healing response
Study
mousen: not reported in source
Femoral allograft model
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 µg/kg/day · 9 weeksAs given in this study (mouse).
Source sentences
Summary
Only the high dose (40 µg/kg) of PTH(1-34) demonstrated significant effects when given daily over 9 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we completed a comprehensive study in the murine femoral allograft model, to assess the effects of dose (0.4, 4, and 40 µg/kg/day) and various treatment regimens on radiographic, histologic, and biomechanical healing at 2, 4, and 9 weeks.
Report a problemFND-2195654201
02AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, delayed short-course teriparatide produced biomechanical results equivalent to prolonged immediate treatment.
In plain wordsIn mice, delayed short teriparatide treatment gave equivalent mechanical healing to prolonged immediate treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBiomechanical healing with delayed short treatment
Study
mousen: not reported in source
Femoral allograft model
Comparator
Immediate daily treatment for 9 weeks
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 2 to 6 weeks postoperativelyAs given in this study (mouse).
Source sentences
Summary
Remarkably, equivalent biomechanical results were obtained with delayed, short treatment from 2 to 6 weeks that did not induce a significant increase in endochondral bone formation and callus volume.
2 context sentences(design, population, supporting numbers)
Summary · context
Only the high dose (40 µg/kg) of PTH(1-34) demonstrated significant effects when given daily over 9 weeks.
Summary · context
To address this, we completed a comprehensive study in the murine femoral allograft model, to assess the effects of dose (0.4, 4, and 40 µg/kg/day) and various treatment regimens on radiographic, histologic, and biomechanical healing at 2, 4, and 9 weeks.
Report a problemFND-2195654202
03AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, delayed short-course teriparatide did not significantly increase endochondral bone formation.
In plain wordsIn mice, delayed short teriparatide treatment did not significantly increase cartilage-based bone formation.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeEndochondral bone formation with delayed treatment
Study
mousen: not reported in source
Femoral allograft model
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 2 to 6 weeks postoperativelyAs given in this study (mouse).
Source sentences
Summary
Remarkably, equivalent biomechanical results were obtained with delayed, short treatment from 2 to 6 weeks that did not induce a significant increase in endochondral bone formation and callus volume.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we completed a comprehensive study in the murine femoral allograft model, to assess the effects of dose (0.4, 4, and 40 µg/kg/day) and various treatment regimens on radiographic, histologic, and biomechanical healing at 2, 4, and 9 weeks.
Report a problemFND-2195654203
04AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, delayed short-course teriparatide did not significantly increase callus volume.
In plain wordsIn mice, delayed short teriparatide treatment did not significantly increase callus volume.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCallus volume with delayed treatment
Study
mousen: not reported in source
Femoral allograft model
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 2 to 6 weeks postoperativelyAs given in this study (mouse).
Source sentences
Summary
Remarkably, equivalent biomechanical results were obtained with delayed, short treatment from 2 to 6 weeks that did not induce a significant increase in endochondral bone formation and callus volume.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we completed a comprehensive study in the murine femoral allograft model, to assess the effects of dose (0.4, 4, and 40 µg/kg/day) and various treatment regimens on radiographic, histologic, and biomechanical healing at 2, 4, and 9 weeks.
Report a problemFND-2195654204
05AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, early short-course teriparatide produced osteogenic effects similar to prolonged immediate treatment.
In plain wordsIn mice, early short teriparatide treatment produced bone-forming effects similar to prolonged immediate treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeOsteogenic effects with early short treatment
Study
mousen: not reported in source
Femoral allograft model
Comparator
Immediate daily treatment for 9 weeks
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 to 5 weeks postoperativelyAs given in this study (mouse).
Source sentences
Summary
In contrast, PTH(1-34) treatment from 1 to 5 weeks postop demonstrated similar osteogenic effects as immediate daily treatment for 9 weeks, but failed to achieve a significant increase in biomechanics at 9 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we completed a comprehensive study in the murine femoral allograft model, to assess the effects of dose (0.4, 4, and 40 µg/kg/day) and various treatment regimens on radiographic, histologic, and biomechanical healing at 2, 4, and 9 weeks.
Report a problemFND-2195654205
06AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, early short-course teriparatide did not significantly increase biomechanics at 9 weeks.
In plain wordsIn mice, early short teriparatide treatment did not significantly improve mechanical properties at 9 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeBiomechanics with early short treatment
Study
mousen: not reported in source
Femoral allograft model
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · 1 to 5 weeks postoperativelyAs given in this study (mouse).
Source sentences
Summary
In contrast, PTH(1-34) treatment from 1 to 5 weeks postop demonstrated similar osteogenic effects as immediate daily treatment for 9 weeks, but failed to achieve a significant increase in biomechanics at 9 weeks.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we completed a comprehensive study in the murine femoral allograft model, to assess the effects of dose (0.4, 4, and 40 µg/kg/day) and various treatment regimens on radiographic, histologic, and biomechanical healing at 2, 4, and 9 weeks.
Report a problemFND-2195654206
07AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, delayed teriparatide enhanced intramembranous bone formation at the graft-host junction.
In plain wordsIn mice, delayed teriparatide enhanced direct bone formation where the graft met host bone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseIntramembranous bone formation at graft-host junction
Study
mousen: not reported in source
Femoral allograft model
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
MicroCT and histologic analyses demonstrated that the 2-week delay in treatment allowed for timely completion of the endochondral phase, such that the prominent effects of PTH(1-34) were enhanced intramembranous bone formation and remodeling at the graft-host junction.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we completed a comprehensive study in the murine femoral allograft model, to assess the effects of dose (0.4, 4, and 40 µg/kg/day) and various treatment regimens on radiographic, histologic, and biomechanical healing at 2, 4, and 9 weeks.
Report a problemFND-2195654207
08AnimalAnimal study (in vivo)Efficacy outcome
In mice with femoral allografts, delayed teriparatide enhanced remodeling at the graft-host junction.
In plain wordsIn mice, delayed teriparatide enhanced bone remodeling where the graft met host bone.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseRemodeling at graft-host junction
Study
mousen: not reported in source
Femoral allograft model
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated
Source sentences
Summary
MicroCT and histologic analyses demonstrated that the 2-week delay in treatment allowed for timely completion of the endochondral phase, such that the prominent effects of PTH(1-34) were enhanced intramembranous bone formation and remodeling at the graft-host junction.
1 context sentence(design, population, supporting numbers)
Summary · context
To address this, we completed a comprehensive study in the murine femoral allograft model, to assess the effects of dose (0.4, 4, and 40 µg/kg/day) and various treatment regimens on radiographic, histologic, and biomechanical healing at 2, 4, and 9 weeks.
Report a problemFND-2195654208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.